Migraine: a treatment that works even before the headache starts

Migraines may soon be managed before the first symptoms even appear. Recent scientific advancements reveal that early treatment could stop an attack before it fully develops. This approach could dramatically improve the lives of millions affected by this condition.

The treatment in question, ubrogepant, is an inhibitor of the calcitonin gene-related peptide (CGRP), a key player in the migraine process. According to a study published in Neurology, administering ubrogepant at the first prodromal signs can prevent a migraine from progressing.


Ubrogepant has shown significant efficacy in reducing activity limitations and improving patient satisfaction compared to a placebo. Those treated reported being significantly more functional 24 hours after taking the medication. This finding is especially noteworthy because it targets the prodromal phase of migraines, which is often overlooked. Early warning signs, such as increased sensitivity to light and sound, fatigue, or dizziness, appear before the actual migraine pain sets in.

The study involved 518 participants, all able to identify early symptoms of their attacks. The results showed that those who took ubrogepant were 73% more likely to report having "no disability" two hours after administration, compared to the placebo group. Additionally, eight hours after treatment, a higher percentage of participants on ubrogepant reported feeling "satisfied" or "very satisfied" with the treatment.

This suggests that ubrogepant not only prevents attacks but also helps maintain a normal quality of life during the prodromal phase. However, the study also raises questions regarding the long-term effectiveness of ubrogepant. Researchers emphasize the need for further clinical trials to validate these findings in broader and more diverse conditions.

Early treatment of migraines could revolutionize how this condition is managed. Currently, medications are often taken after the headache has already developed, which limits their effectiveness. Ubrogepant could thus offer a new strategy to control migraines at their onset.

Nonetheless, despite the promising results, it remains crucial to continue research to assess potential side effects and the durability of this approach. Millions of migraine sufferers are likely eagerly awaiting to see if this new therapy could indeed transform their daily lives.